Stock ARVN ARVINAS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Arvinas, Inc.

Equities

ARVN

US04335A1051

Real-time Estimate Cboe BZX
Other stock markets
 12:15:56 2024-05-06 EDT 		5-day change 1st Jan Change
31.91 USD -2.77% Intraday chart for Arvinas, Inc. +1.43% -21.39%
04-24 Arvinas, Inc. Appoints Randy Teel as Chief Business Officer CI
04-15 H.C. Wainwright Cuts Price Target on Arvinas to $87 From $90, Maintains Buy Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Arvinas to Present at Upcoming Investor Conferences
GL
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
GL
Arvinas : 2024 Proxy Statement
PU
Arvinas enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer
AQ
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
AQ
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
GL
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
GL
Arvinas to Participate in Upcoming Investor Conferences
GL
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
GL
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AQ
Arvinas Announces Chief Financial Officer Transition
GL
Arvinas Announces Chief Financial Officer Transition
AQ
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
GL
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
AQ
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
GL
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
AQ
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
GL
Arvinas Appoints Jared Freedberg as General Counsel
GL
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib and Plans to Expand Vepdegestrant Development Program
AQ
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARVN Stock
  4. News Arvinas, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW